-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to ASAS/EULAR recommendations, non-steroidal anti-inflammatory drugs (NSAIDs) are the first-line treatment for AS; however, some patients may not respond adequately and others require continuous use to avoid symptoms; considering potential NSAID-related risks and/or side effects, which are not always possible
Infliximab is a human/mouse (75% and 24%, respectively) IgG1K allotype-neutralizing monoclonal chimeric antibody with specificity and high affinity for human tumor necrosis factor-alpha
Etanercept is a dimeric fusion protein of human TNF receptor linked to the Fc portion of human IgG1 [31]
Source: Garcia-Montoya L, Emery P, Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials.
Garcia-Montoya L, Emery P, Disease modification in ankylosing spondylitis with TNF inhibitors: spotlight on early phase clinical trials.
Expert Opin Investig Drugs 2021 Nov;30(11)
Leave a comment here